LSRM Stock Overview
A clinical-stage biotechnology company, engages in the research and development of immune system therapy for the treatment of cancer and other diseases in the United States.
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
CEL-SCI Corporation Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.96 |
| 52 Week High | US$2.82 |
| 52 Week Low | US$0.92 |
| Beta | 0.66 |
| 11 Month Change | 1.32% |
| 3 Month Change | -10.76% |
| 1 Year Change | -13.74% |
| 33 Year Change | -89.41% |
| 5 Year Change | -87.32% |
| Change since IPO | -98.94% |
Recent News & Updates
Recent updates
Shareholder Returns
| LSRM | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | 0.9% | 2.0% | -1.1% |
| 1Y | -13.7% | -12.1% | 10.8% |
Return vs Industry: LSRM underperformed the German Biotechs industry which returned -12.1% over the past year.
Return vs Market: LSRM underperformed the German Market which returned 10.8% over the past year.
Price Volatility
| LSRM volatility | |
|---|---|
| LSRM Average Weekly Movement | 9.6% |
| Biotechs Industry Average Movement | 6.4% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in DE Market | 10.6% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: LSRM's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: LSRM's weekly volatility has decreased from 17% to 10% over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1983 | n/a | Geert Kersten | cel-sci.com |
CEL-SCI Corporation, a clinical-stage biotechnology company, engages in the research and development of immune system therapy for the treatment of cancer and other diseases in the United States. The company’s lead immunotherapy is Multikine, which has completed Phase 3 clinical trials for the potential treatment of certain head and neck cancers. It is also developing products based on its proprietary technology Ligand Epitope Antigen Presentation System (LEAPS) technology, a patented T-cell modulation process that stimulates the human immune system to fight bacterial, viral, parasitic infections, autoimmune conditions, allergies, transplantation rejections, and cancer.
CEL-SCI Corporation Fundamentals Summary
| LSRM fundamental statistics | |
|---|---|
| Market cap | €58.88m |
| Earnings (TTM) | -€26.54m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-2.2x
P/E RatioIs LSRM overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| LSRM income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$18.95m |
| Gross Profit | -US$18.95m |
| Other Expenses | US$10.15m |
| Earnings | -US$29.10m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.47 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did LSRM perform over the long term?
See historical performance and comparison